Hybrid-Designed Inhibitors of p38 MAP Kinase UtilizingN-Arylpyridazinones

Steven L. Colletti; Jessica L. Frie; Elizabeth C. Dixon; Suresh B. Singh; Bernard K. Choi; Giovanna Scapin; Catherine E. Fitzgerald; Sanjeev Kumar; E.A. Nichols; Stephen J. O’Keefe; Edward A. O’Neill; Gene Porter; Koppara Samuel; Dennis M. Schmatz; Cheryl D. Schwartz; Wesley L. Shoop; Chris M. Thompson; James E. Thompson; Ruixiu Wang; Andrea Woods; Dennis M. Zaller; James B. Doherty

doi:10.1021/jm025585h

Abstract

This is the authors' abstract. We don't add key points for this paper.

Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Colletti et al. (2002) studied this question.

synapsesocial.com/papers/6a9c8549b245de61514a4ed6 https://doi.org/10.1021/jm025585h

View Full Paper

Ask AI

Bookmark

Share

Hybrid-Designed Inhibitors of p38 MAP Kinase UtilizingN-Arylpyridazinones

Abstract

Ask about this paper

Discussion

Cite This Study

Hybrid-Designed Inhibitors of p38 MAP Kinase UtilizingN-Arylpyridazinones

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading